Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q1 2026 · 10-Q
Revenue$0.00$0.00−100.0% vs Q1 2025 Net Income-$19.68M-$19.68MN/M vs Q1 2025 EPS Diluted-$0.28-$0.28N/M vs Q1 2025 Operating Income-$21,949,993N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
Free Cash Flowderived-$21,591,316N/M ended Mar 31, 2026 · filed May 13, 2026 · 43 d after period end